<DOC>
	<DOCNO>NCT01303796</DOCNO>
	<brief_summary>This Phase 3 study ass two drug regimen initial treatment patient least 70 year age newly diagnose acute myeloid leukemia ( AML ) doctor recommend use standard intensive treatment patient decide receive standard intensive treatment fully inform benefit risk his/her doctor . The two drug regimen sapacitabine administer alternating cycle decitabine , decitabine alone . The purpose study learn drug regimen likely keep AML check long possible .</brief_summary>
	<brief_title>A Study Oral Sapacitabine Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>This multicenter , randomize , Phase 3 study compare two drug regimen ( arm ) front-line treatment elderly patient age 70 year old newly diagnose acute myeloid leukemia ( AML ) candidate intensive induction chemotherapy . In Arm A , sapacitabine administer alternate cycle decitabine , Arm C decitabine administer alone . The primary efficacy endpoint overall survival . The study design demonstrate improvement overall survival Arm A versus Arm C .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Newly diagnose AML base WHO classification Age 70 year old treatment choice lowintensity therapy investigator assessment refuse intensive induction therapy recommend investigator ECOG performance status 02 Adequate renal function Adequate liver function Able swallow capsule Agree practice effective contraception Ability understand willingness sign inform consent form AML subtype acute promyelocytic leukemia extramedullary myeloid tumor without bone marrow involvement Having receive systemic anticancer therapy AML receive treatment hypomethylating agent cytotoxic chemotherapy precede MDS MPD Known suspect central nervous system ( CNS ) involvement leukemia Uncontrolled intercurrent illness Known hypersensitivity decitabine Known HIVpositive</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>AML</keyword>
</DOC>